Press Releases

Press Releases

  1. BTG plc: Voraxaze® (glucarpidase) licensed to Ohara Pharmaceuticals in Japan

  2. BTG plc: Interim Results

  3. BTG plc: Garry Watts to succeed Dr John Brown as non-executive Chairman

  4. BTG plc: Directorate Change

  5. BTG plc: Close Period Update

  6. BTG plc: FDA accepts Biologics License Application file for Voraxaze® (glucarpidase) and grants Priority Review

  7. BTG plc: ZYTIGA™ (abiraterone acetate) approved in the EU

  8. BTG plc: Annual General Meeting and Interim Management Statement

  9. BTG plc: Top-Line Results from First Phase 3 Study of Alemtuzumab (Lemtrada™) in Multiple Sclerosis Reported

  10. BTG Acquires US Marketing Rights to Wellstat’s Investigational Antidote for 5-FU Overexposure

  11. BTG plc: Final Results

  12. BTG plc: AstraZeneca ends CM-3 development and option agreement

  13. BTG plc: ZYTIGA™ (abiraterone acetate) Approved in the US

  14. BTG plc: Close Period Update

  15. BTG plc: DEFEND-1 study of otelixizumab in type 1 diabetes did not meet primary endpoint

  16. Offer Update: Admission of New BTG Shares

  17. Offer Update: Scheme Effective

  18. BTG plc: Interim Management Statement

  19. Offer Update: Court sanction of the Scheme of Arrangement and timetable update

  20. BTG to present at the J.P. Morgan Annual Healthcare Conference

  21. Offer Update: Result of BTG Shareholder Meeting